EXEL Quote, Financials, Valuation and Earnings

Castle Biosciences, Inc. has a net margin of 40.85% compared to Exelixis, Inc.'s net margin of -0.6%. Exelixis, Inc.'s return on equity of 36.46% beat Castle Biosciences, Inc.'s return on equity of -2.71%.

Exelixis, Inc. has a consensus price target of $47.17, signalling upside risk potential of 8.11%. On the other hand Castle Biosciences, Inc. has an analysts' consensus of $48.13 which suggests that it could grow by 64.76%. Given that Castle Biosciences, Inc. has higher upside potential than Exelixis, Inc., analysts believe Castle Biosciences, Inc. is more attractive than Exelixis, Inc..

Exelixis, Inc. has a beta of 0.417, which suggesting that the stock is 58.311% less volatile than S&P 500. In comparison Castle Biosciences, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.16%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Castle Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis, Inc. pays -- of its earnings as a dividend. Castle Biosciences, Inc. pays out -- of its earnings as a dividend.

Exelixis, Inc. quarterly revenues are $598.7M, which are larger than Castle Biosciences, Inc. quarterly revenues of $83M. Exelixis, Inc.'s net income of $244.5M is higher than Castle Biosciences, Inc.'s net income of -$501K. Notably, Exelixis, Inc.'s price-to-earnings ratio is 15.67x while Castle Biosciences, Inc.'s PE ratio is 30.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.30x versus 2.50x for Castle Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of 40.85% compared to Exelixis, Inc.'s net margin of 27.55%. Exelixis, Inc.'s return on equity of 36.46% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Exelixis, Inc. has a consensus price target of $47.17, signalling upside risk potential of 8.11%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $155.41 which suggests that it could grow by 2.65%. Given that Exelixis, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Exelixis, Inc. is more attractive than Gilead Sciences, Inc..

Exelixis, Inc. has a beta of 0.417, which suggesting that the stock is 58.311% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.09% to investors and pays a quarterly dividend of $0.79 per share. Exelixis, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.61% of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Exelixis, Inc. quarterly revenues are $598.7M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.9B. Exelixis, Inc.'s net income of $244.5M is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Exelixis, Inc.'s price-to-earnings ratio is 15.67x while Gilead Sciences, Inc.'s PE ratio is 22.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.30x versus 6.46x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 40.85% compared to Exelixis, Inc.'s net margin of 18.06%. Exelixis, Inc.'s return on equity of 36.46% beat Merck & Co., Inc.'s return on equity of 39.63%.

Exelixis, Inc. has a consensus price target of $47.17, signalling upside risk potential of 8.11%. On the other hand Merck & Co., Inc. has an analysts' consensus of $126.00 which suggests that it could grow by 3.06%. Given that Exelixis, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Exelixis, Inc. is more attractive than Merck & Co., Inc..

Exelixis, Inc. has a beta of 0.417, which suggesting that the stock is 58.311% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.68% to investors and pays a quarterly dividend of $0.85 per share. Exelixis, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Exelixis, Inc. quarterly revenues are $598.7M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Exelixis, Inc.'s net income of $244.5M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Exelixis, Inc.'s price-to-earnings ratio is 15.67x while Merck & Co., Inc.'s PE ratio is 16.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.30x versus 4.72x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Natera, Inc. has a net margin of 40.85% compared to Exelixis, Inc.'s net margin of -14.78%. Exelixis, Inc.'s return on equity of 36.46% beat Natera, Inc.'s return on equity of -26.6%.

Exelixis, Inc. has a consensus price target of $47.17, signalling upside risk potential of 8.11%. On the other hand Natera, Inc. has an analysts' consensus of $257.20 which suggests that it could grow by 21.25%. Given that Natera, Inc. has higher upside potential than Exelixis, Inc., analysts believe Natera, Inc. is more attractive than Exelixis, Inc..

Exelixis, Inc. has a beta of 0.417, which suggesting that the stock is 58.311% less volatile than S&P 500. In comparison Natera, Inc. has a beta of 1.636, suggesting its more volatile than the S&P 500 by 63.611%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis, Inc. pays -- of its earnings as a dividend. Natera, Inc. pays out -- of its earnings as a dividend.

Exelixis, Inc. quarterly revenues are $598.7M, which are larger than Natera, Inc. quarterly revenues of $592.2M. Exelixis, Inc.'s net income of $244.5M is higher than Natera, Inc.'s net income of -$87.5M. Notably, Exelixis, Inc.'s price-to-earnings ratio is 15.67x while Natera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.30x versus 13.52x for Natera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.